Hamid, Omid

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

Glitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 87

Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials

Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G., de Pril, V., Ibrahim, R., Hoos, A., & O'Day, S. (2009) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 58

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 28

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

Chesney, J., Collichio, F., Andtbacka, R. H. I., Puzanov, I., Glaspy, J., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., et al. (2016) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 15